Etienne Morel’s talk at the Virology Virtual Conference

Published on 26/03/2021

Etienne Morel, collaborator of ENYO Pharma, gave a talk describing the results of our collaboration entitled “From virus-host molecular crosstalk to ER-mitochondria membrane interface mobilization in innate immunity” at the Virology Virtual Conference on March the 23th :
Conference description

Read next in 'Latest news'

• La Phase 2
• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)